FUXION BIOTECH (ESPAÑA) SL
Company details
- Active NIF/CIF: B85744829
-
-
-
-
Address: C/ DOCTOR FLEMING 3 - 1º DERECHA (MADRID)
-
-
Featured products:
More information on FUXION BIOTECH (ESPAÑA) SL
-
03/07/2015 | BORME act no.: 273685 | Register: MADRIDCambio de denominación social
-
01/07/2015 | BORME act no.: 269897 | Register: MADRIDNombramientos
-
03/05/2013 | BORME act no.: 204227 | Register: MADRIDCambio de domicilio social
-
11/11/2010 | BORME act no.: 1024615 | Register: MADRIDDepósito de cuentas anuales (Octubre de 2010)
-
04/08/2009 | BORME act no.: 343313 | Register: MADRIDConstitución
-
04/08/2009 | BORME act no.: 343313 | Register: MADRIDNombramientos
Other information
The CIF assigned to FUXION BIOTECH (ESPAÑA) SL is B85744829, and its commercial status is active. The company is engaged in economic activities classified under the CNAE 62 - Programación, consultoría y otras actividades relacionadas con la informática. Additionally, it is categorized with the SIC code 7389 - Servicios empresariales.
FUXION BIOTECH (ESPAÑA) SL employs approximately Between 10 and 49 employees and records an annual turnover of less than 2 million euros. The company is registered in the Commercial Registry of Madrid, and has 2 registration charges. The most recent announcement in Borme was published on 03/07/2015, while the last deposit of ordinary annual accounts corresponds to the year -.
To find out the contact information of FUXION BIOTECH (ESPAÑA) SL, such as the telephone number, postal address, or website, you can access the Company Data module.
If you wish to obtain additional information about FUXION BIOTECH (ESPAÑA) SL, we invite you to consult any of the available financial reports, the Annual Accounts of the company, or review the incidents of defaults registered in the RAI delinquency file.
The financial, commercial, and legal information about FUXION BIOTECH (ESPAÑA) SL comes from official data sources and is automatically updated every day.
Do you want to know more about FUXION BIOTECH (ESPAÑA) SL??
Find out more about this company by consulting these reports: